ADICET-ADI-001-BCELL
Phase I
OPEN TO ACCRUAL
A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-Engineered Allogeneic Gamma-Delta T Cells in Adults with Refractory B-Cell Malignancies
ADICET-ADI-001-LTFU
Phase N/A
OPEN TO ACCRUAL
Long-Term Follow-Up Protocol for Subjects Treated with Adicet Allogeneic Gamma Delta CAR T Cell Investigational Products
ALLOGENE-ALLO-501A-201
Phase I/II
OPEN TO ACCRUAL
A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogeneic CAR T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody, in Subjects with Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
IIT-SHAH-IL7-IL15-CD20-19
Phase I/II
OPEN TO ACCRUAL
Phase I/II Study of Tandem, Bispecific Anti-CD19 Anti-CD20 CAR-T Cells for Patients with Relapsed and/or Refractory B Cell Malignancies
MILTENYI-MB-CART2019-1-DLBCL
Phase II
OPEN TO ACCRUAL
A Multi-Center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and Anti-CD19 Specific Chimeric Antigen Receptor in Subjects with Relapsed and/or Refractory Diffuse Large B Cell Lymphoma